Frontiers in Immunology (May 2021)

Development and Validation of a Novel Prognostic Model for Acute Myeloid Leukemia Based on Immune-Related Genes

  • Ran Li,
  • Zuoyou Ding,
  • Peng Jin,
  • Shishuang Wu,
  • Ge Jiang,
  • Rufang Xiang,
  • Wenfang Wang,
  • Zhen Jin,
  • Xiaoyang Li,
  • Kai Xue,
  • Xiaolu Wu,
  • Junmin Li

DOI
https://doi.org/10.3389/fimmu.2021.639634
Journal volume & issue
Vol. 12

Abstract

Read online

The prognosis of acute myeloid leukemia (AML) is closely related to immune response changes. Further exploration of the pathobiology of AML focusing on immune-related genes would contribute to the development of more advanced evaluation and treatment strategies. In this study, we established a novel immune-17 signature based on transcriptome data from The Cancer Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx) databases. We found that immune biology processes and transcriptional dysregulations are critical factors in the development of AML through enrichment analyses. We also formulated a prognostic model to predict the overall survival of AML patients by using LASSO (Least Absolute Shrinkage and Selection Operator) regression analysis. Furthermore, we incorporated the immune-17 signature to improve the prognostic accuracy of the ELN2017 risk stratification system. We concluded that the immune-17 signature represents a novel useful model for evaluating AML survival outcomes and may be implemented to optimize treatment selection in the next future.

Keywords